Afamelanotide + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Erythropoietic Protoporphyria
Conditions
Erythropoietic Protoporphyria
Trial Timeline
Apr 1, 2010 → Apr 1, 2011
NCT ID
NCT01097044About Afamelanotide + Placebo
Afamelanotide + Placebo is a phase 2 stage product being developed by Clinuvel Pharmaceuticals for Erythropoietic Protoporphyria. The current trial status is completed. This product is registered under clinical trial identifier NCT01097044. Target conditions include Erythropoietic Protoporphyria.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04525157 | Phase 2 | Completed |
| NCT01605136 | Phase 3 | Completed |
| NCT04704713 | Phase 3 | Completed |
| NCT01097044 | Phase 2 | Completed |
| NCT00979745 | Phase 3 | Completed |
| NCT04425746 | Phase 2 | Completed |
| NCT04053270 | Phase 3 | Completed |
Competing Products
8 competing products in Erythropoietic Protoporphyria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DISC-1459 + DISC-1459 + Placebo | Disc Medicine | Phase 2 | 47 |
| Placebo + DISC-1459 | Disc Medicine | Phase 3 | 72 |
| DISC-1459 + DISC-1459 | Disc Medicine | Phase 2/3 | 60 |
| Afamelanotide | Clinuvel Pharmaceuticals | Phase 3 | 69 |
| Afamelanotide + Placebo | Clinuvel Pharmaceuticals | Phase 3 | 69 |
| Afamelanotide 16mg implant | Clinuvel Pharmaceuticals | Phase 1/2 | 33 |
| Afamelanotide + Placebo | Clinuvel Pharmaceuticals | Phase 3 | 69 |
| Afamelanotide + Placebo | Clinuvel Pharmaceuticals | Phase 3 | 69 |